{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:03:03Z","timestamp":1789344183678,"version":"build-2803163510"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Biol Markers"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Multigene tests have emerged as valuable tools in guiding adjuvant chemotherapy decisions for patients with ER-positive\/HER2-negative early breast cancer. This study applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the quality of evidence supporting the clinical utility of these tests. We focused on OncotypeDX\u00ae and MammaPrint\u00ae, the two tests evaluated in prospective randomized trials. The analysis was structured around the clinical question of whether these tests should be recommended for patients with ER-positive, HER2-negative, lymph node-negative or up to 3 lymph nodes-positive invasive breast cancer to guide adjuvant chemotherapy decisions. Our findings reveal that OncotypeDX\u00ae demonstrates high clinical utility in sparing chemotherapy for older\/postmenopausal patients, with convincing quality of evidence for both node-negative and node-positive patients. The clinical utility of MammaPrint\u00ae appears more controversial, with conflicting results between node-negative and node-positive patients. A particularly critical aspect remains the clinical usefulness of these tests in younger\/premenopausal women, where the benefit of adjuvant chemotherapy was shown but with potential biases in the study designs. Despite the established role of multigene tests and their availability in Italy since 2021, their uptake in clinical practice remains suboptimal. This formal appraisal of the clinical utility of genomic tests, particularly OncotypeDX\u00ae, aims to reinforce their fundamental role in personalizing adjuvant treatment decisions and optimizing resource allocation. The study underscores the importance of these tests in sparing unnecessary chemotherapy toxicities and costs, while emphasizing the need for further research to address remaining uncertainties, especially in younger patient populations.<\/jats:p>","DOI":"10.1177\/03936155261471908","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:39:06Z","timestamp":1789159146000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multigene testing to guide clinical adjuvant decisions in breast cancer: An overview focused on the assessment of the quality of evidence with the grading of recommendations assessment, development and evaluation (GRADE) approach"],"prefix":"10.1177","volume":"41","author":[{"given":"Maria Vittoria","family":"Dieci","sequence":"first","affiliation":[{"name":"University of Padova"},{"name":"Istituto Oncologico Veneto IOV-IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-5344","authenticated-orcid":false,"given":"Pierfranco","family":"Conte","sequence":"additional","affiliation":[{"name":"Periplo Foundation President, Genova"},{"name":"S Camillo Hospital IRCCS, Venice, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[{"name":"ASST Cremona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[{"name":"Ospedale Perrino ASL Brindisi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[{"name":"University of Naples Federico II"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Longo","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria di Modena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni L.","family":"Pappagallo","sequence":"additional","affiliation":[{"name":"IRCCS \u201cSacred Heart-Don Calabria\u201d Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[{"name":"University of Padova"},{"name":"Istituto Oncologico Veneto IOV-IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00758-0"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701830"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.07.035"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003451"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq683"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705032"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050178"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61625-5"},{"key":"e_1_3_4_12_2","first-page":"658","article-title":"Genomics of adjuvant therapy for breast cancer","volume":"24","author":"Kim SR","year":"2012","unstructured":"Kim SR, Paik S. Genomics of adjuvant therapy for breast cancer. Curr Opin Oncol 2012; 24: 658\u2013664.","journal-title":"Curr Opin Oncol"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61539-0"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32139"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.01973.x"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804710"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108873"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00007-3"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt146"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0129-6"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0926"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803164"},{"key":"e_1_3_4_24_2","volume-title":"Modalit\u00e0 di riparto e requisiti di utilizzo del fondo per i test genomici ormonoresponsivi nel carcinoma mammario in stadio precoce","author":"Ministero della Salute","year":"2021","unstructured":"Ministero della Salute. Modalit\u00e0 di riparto e requisiti di utilizzo del fondo per i test genomici ormonoresponsivi nel carcinoma mammario in stadio precoce. Gazz Uff Repubblica, 2021, vol 156."},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0322"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0103"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.04.003"}],"container-title":["The International Journal of Biological Markers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03936155261471908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03936155261471908","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03936155261471908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:16:49Z","timestamp":1789341409000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03936155261471908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["10.1177\/03936155261471908"],"URL":"https:\/\/doi.org\/10.1177\/03936155261471908","relation":{},"ISSN":["0393-6155","1724-6008"],"issn-type":[{"value":"0393-6155","type":"print"},{"value":"1724-6008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"03936155261471908"}}